

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

**Draft Guidance on Iomeprol**

**December 2025**

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

---

<b>Active Ingredient:</b>	Iomeprol
<b>Dosage Form:</b>	Solution
<b>Route:</b>	Intravenous
<b>Strengths:</b>	15 gm Iodine/50 mL (300 mg Iodine/mL), 17.5 gm Iodine/50 mL (350 mg Iodine/mL), 20 gm Iodine/50 mL (400 mg Iodine/mL), 25 gm Iodine/100 mL (250 mg Iodine/mL), 30 gm Iodine/100 mL (300 mg Iodine/mL), 35 gm Iodine/100 mL (350 mg Iodine/mL), 40 gm Iodine/100 mL (400 mg Iodine/mL), 45 gm Iodine/150 mL (300 mg Iodine/mL), 52.5 gm Iodine/150 mL (350 mg Iodine/mL), 60 gm Iodine/150 mL (400 mg Iodine/mL), 60 gm Iodine/200 mL (300 mg Iodine/mL), 70 gm Iodine/200 mL (350 mg Iodine/mL), 80 gm Iodine/200 mL (400 mg Iodine/mL)
<b>Recommended Study:</b>	Request for waiver of in vivo bioequivalence study requirements

To qualify for a waiver from the requirement for submission of evidence of in vivo bioequivalence on the basis that bioequivalence is self-evident under 21 CFR 320.22(b)(1), a generic iomeprol intravenous solution product should be qualitatively (Q1)<sup>1</sup> and quantitatively (Q2)<sup>2</sup> the same as the reference listed drug (RLD).

---

<sup>1</sup> Q1 (Qualitative sameness) means that the test product uses the same inactive ingredient(s) as the RLD.

<sup>2</sup> Q2 (Quantitative sameness) means that concentrations of the inactive ingredient(s) used in the test product are within ±5% of those used in the RLD.

An applicant may seek approval of a drug product that differs from the RLD in preservative, buffer, or antioxidant provided that the applicant identifies and characterizes the differences and provides information demonstrating that the differences do not affect the safety or efficacy of the proposed drug product.<sup>3</sup>

---

**Document History:** Recommended December 2025

**Unique Agency Identifier:** PSG\_216017

---

<sup>3</sup> 21CFR 314.94(a)(9)(iii).